uniQure Biopharma BV

Meibergdreef 61,
Amsterdam, 1105 BA
Netherlands,
31 20 566 7394
www.uniqure.com

uniQure Biopharma BV is a gene therapy company that developed the first and only gene therapy product to receive regulatory approval in the European Union. Gene therapy is a technique for correcting defective or missing genes that cause diseases. uniQure is primarily focused on rare genetic diseases, and will also start developing gene therapies for chronic and degenerative diseases that affect larger populations.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.2/yr) # 1 - 1 - - - 2
vol $3M $3M
Sell (0.0/yr) # - - - - - - 0
  2

Top M&A Advisors

Financial Deals
Join to Access.
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest InoCard GmbH
$3M (2014-08-11)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

According to our data here at Mergr, uniQure Biopharma BV has acquired 2 companies, including 1 in the last 5 years.

uniQure Biopharma BV’s largest acquisition to date was in 2014, when it acquired InoCard for $3M. uniQure Biopharma BV has acquired in 2 countries. The Company’s most targeted sectors include life science (100%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to uniQure Biopharma BV’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 113K M&A Transactions
  • 123K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.